Exhibit 99.1 Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress Enrollment completed in September and dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease Updated Phase 1 data from RP-A501 for Danon disease anticipated at American Heart Association's 2024 Late-Breaking Scientific Sessions Enrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM; Preliminary data expected in the first half of 2025 Rolling BLA submissi ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Rocket Pharmaceuticals, Inc. (RCKT) announced that it has completed patient enrollment in a pivotal phase II study evaluating its investigational gene therapy candidate, RP-A501, for treating male patients with Danon disease. Danon disease is a rare X-linked inherited disorder caused by mutations in the LAMP2 gene. Per the company, an estimated 15,000 to 30,000 patients suffer from Danon disease in the United States and Europe. Currently, the only available treatment for the disease is cardiac transplantati ...

Shares of Rocket Pharmaceuticals (RCKT) have plunged 32.9% in the past six months compared with the industry's decline of 3.4%. The company is developing its gene therapy candidate, Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. In June 2024, the FDA issued a complete response letter (CRL) to Rocket's biologics license application (BLA) seeking approval for Kresladi to treat LAD-I. Per the CRL, the FDA sought "limited" add ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36829 Rocket Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3475813 (State or o ...

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Enrollment of patients ongoing in the pivotal Phase 2 study of RP-A501 for the treatment of Danon disease and the Phase 1 study of RP-A601 to treat PKP2 arrhythmogenic cardiomyopathy Working toward FDA-approval of KRESLADI for severe LAD-I; Commercial infrastructure and capabilities in place for launch Presented long-term KRESLADITM follow-up data from the global Phase 1/2 study for severe LAD-I, results from ...

Rocket Pharmaceuticals (RCKT) announced that the FDA issued a complete response letter (CRL) to its biologics license application (BLA) seeking approval for its gene therapy Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. Per the CRL, the FDA sought 'limited' additional information on the therapy's Chemistry Manufacturing and Controls (CMC), which is a part of the BLA submission. The goal of CMC is to ensure that every batc ...

Rocket Pharmaceuticals' experimental treatment for a rare immune disorder in children was delayed again by the Food and Drug Administration (FDA). Regulators sent a Complete Response Letter to the company, asking for more information on Kresladi. The FDA was initially expected to grant approval in March, but delayed it for three months to complete its review. Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administrat ...

In the reported quarter, general and administrative (G&A) expenses rose 40% year over year to $22.1 million. The upside was driven by an increase in the company's commercial preparation expenses in anticipation of a potential FDA approval for Kresladi in severe LAD-I. A month has gone by since the last earnings report for Rocket Pharmaceuticals (RCKT) . Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release ...

Table of Contents Rocket Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 ...